Baxter International Inc. with ticker code (BAX) now have 14 analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The target price ranges between 105 and 82 with a mean TP of 94.21. With the stocks previous close at 83.22 this would indicate that there is a potential upside of 13.2%. The 50 day moving average now sits at 77.39 while the 200 day moving average is 81.32. The market capitalisation for the company is $41,797m. Company Website: http://www.baxter.com
Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies. It also provides biological products and medical devices, and surgical hemostat and sealant products used in surgical procedures for hemostasis, tissue sealing, and adhesion prevention; premixed and oncology drug platforms, inhaled anesthesia and critical care products, and pharmacy compounding services; and generic injectable pharmaceuticals. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors’ offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules. Baxter International Inc. was founded in 1931 and is headquartered in Deerfield, Illinois.
You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.